- Poster presentation
- Open access
- Published:
Cost implication of antibiotic-associated diarrhoea and the financial impact of probiotic use in its prevention
Critical Care volume 17, Article number: P83 (2013)
Introduction
Antibiotic-associated diarrhoea (AAD) occurs in as many as 30% of patients receiving antibiotics, often leading to increased morbidity, prolonged in-hospital stay and additional healthcare resource utilisation. Age, antibiotics and prolonged postoperative ward and ICU stay have been suggested to be independent risk factors. In such patient populations, probiotics may be used to prevent antibiotic-associated diarrhoea, yet they are not routinely recommended as a component of perioperative care. The aim of this study was to model the long-term costs associated with AAD and to assess the effectiveness of probiotics as a preventive strategy.
Methods
We developed a simulation model to determine clinical costs and outcomes attributable to AAD. To assess the cost-effectiveness of probiotics, as part of a perioperative regime, we constructed a decision tree. The model observes long-term costs and outcomes of probiotics as compared with conventional therapy, from a societal perspective. Input parameters, extracted from meta-analysis, clinical trials and national databases, include incidence numbers, costs and quality-adjusted health states for the remaining life (QALYs). Outcomes assessed were overall costs attributable to ADD and the cost-effectiveness of probiotics, described as costs/QALY.
Results
Our results indicate an estimated incremental lifetime cost of £13,272.53 per ADD patient, largely driven by increased ICU length of stay and readmission rates. The addition of probiotics to the standard perioperative regime is associated with a small survival benefit of 1.2 months, yet a cost reduction of £917.3/ADD patient. The main cost was increased duration of ICU stay and readmissions, which contribute to 85% of total expenses.
Conclusion
AAD is associated with a significant increase in costs from a societal perspective. The provision of probiotics can achieve substantial cost savings and can be recommended as a cost-effective regime in the perioperative setting. Preventing ADD offers a potentially significant reduction of in-hospital costs and resource expenditures.
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Ebm, C., Cecconi, M., Moran, C. et al. Cost implication of antibiotic-associated diarrhoea and the financial impact of probiotic use in its prevention. Crit Care 17 (Suppl 2), P83 (2013). https://doi.org/10.1186/cc12021
Published:
DOI: https://doi.org/10.1186/cc12021